A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors.

Shu-Hui Li,Yi-Wen Li,Ying-Jue Li,Lin-Bo Liu,Qun Zhang,Dan Lu

International journal of general medicine（2023）

引用 0|浏览3

暂无评分

摘要

Anlotinib combined with anti-PD-1 inhibitors demonstrated promising efficacy and tolerable safety for patients with advanced solid tumors in the 2nd or later-line treatment.

查看译文

关键词

anlotinib,anti-pd-1 inhibitor,advanced solid tumors,adverse reactions.

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要